Pliant Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 158
- Market Cap
- $797.1M
- Website
- http://www.pliantrx.com
- Introduction
Pliant Therapeutics, Inc. engages in the discovery and development of therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-?1 signaling inhibition. The company was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2024-02-21
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Pliant Therapeutics, Inc.
- Target Recruit Count
- 77
- Registration Number
- NCT06270706
- Locations
- 🇺🇸
South Texas Accelerated Research Therapeutics (START), Grand Rapids, Michigan, United States
🇺🇸NEXT Virginia, Fairfax, Virginia, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
- First Posted Date
- 2023-10-24
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Pliant Therapeutics, Inc.
- Target Recruit Count
- 360
- Registration Number
- NCT06097260
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Arizona Pulmonary Specialists, Phoenix, Arizona, United States
🇺🇸Dignity Health-St. Josephs Hospital and Medical Center, Phoenix, Arizona, United States
Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809)
- First Posted Date
- 2022-11-18
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Pliant Therapeutics, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT05621252
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-09-25
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- Pliant Therapeutics, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT04565249
- Locations
- 🇺🇸
Advent Health, Orlando, Florida, United States
🇺🇸National Jewish Health, Denver, Colorado, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Pliant Therapeutics, Inc.
- Target Recruit Count
- 121
- Registration Number
- NCT04480840
- Locations
- 🇺🇸
Stanford University School of Medicine, Redwood City, California, United States
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary Fibrosis
- First Posted Date
- 2020-05-21
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Pliant Therapeutics, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT04396756
- Locations
- 🇧🇪
UZ Leuven, Leuven, Belgium
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸The Emory Clinic, Atlanta, Georgia, United States
Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/
- Conditions
- Interventions
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Pliant Therapeutics, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT04072315
- Locations
- 🇺🇸
Stanford Medical Center, Palo Alto, California, United States